Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases

Aishwarya Mary JohnsonDepartment of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Abu Dhabi, United Arab Emirates

https://orcid.org/0000-0002-9030-9954 View further author information

Robert BarigyeDepartment of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Abu Dhabi, United Arab Emirates

https://orcid.org/0000-0002-8420-075X View further author information

Hariharan SaminathanDepartment of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Abu Dhabi, United Arab EmiratesCorrespondence[email protected]

https://orcid.org/0000-0003-0009-7028 View further author information

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Shaohua Xu, Huicheng Yuan, Ling Li, Kai Yang & Liangcun Zhao. (2024) Computational screening of potential bromodomain-containing protein 2 inhibitors for blocking SARS-CoV-2 infection through pharmacophore modeling, molecular docking and molecular dynamics simulation. Arabian Journal of Chemistry 17:1, pages 105365.
Crossref

Mingtao Liu, Zhiman Liang, Zhangkai J. Cheng, Li Liu, Qiwen Liu, Yiyin Mai, Huihuang Chen, Baoying Lei, Shangwei Yu, Huihui Chen, Peiyan Zheng & Baoqing Sun. (2023) SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges. Reviews in Medical Virology 33:5.
Crossref

Zhuo Li, Huiyuan Zhang, Xiaxia Yu, Yusi Zhang & Lihua Chen. (2023) Construction of a Hantaan Virus Phage Antibody Library and Screening for Potential Neutralizing Activity. Viruses 15:5, pages 1034.
Crossref

Mingtao Liu, Hui Gan, Zhiman Liang, Li Liu, Qiwen Liu, Yiyin Mai, Huihuang Chen, Baoying Lei, Shangwei Yu, Huihui Chen, Peiyan Zheng & Baoqing Sun. (2023) Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. Frontiers in Microbiology 14.
Crossref

Adriana Fodor, Brandusa Tiperciuc, Cezar Login, Olga H. Orasan, Andrada L. Lazar, Cristina Buchman, Patricia Hanghicel, Adela Sitar-Taut, Ramona Suharoschi, Romana Vulturar & Angela Cozma. (2021) Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19—Mechanisms and Therapeutic Targets. Oxidative Medicine and Cellular Longevity 2021, pages 1-15.
Crossref

Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Kristian Thorlund, Lehana Thabane, Gordon H. Guyatt, Jamie I. Forrest, Alla V. Glushchenko, Cameron Chernecki, Paula McKay, Sheila Sprague, Ofir Harari, Hinda Ruton, Craig R. Rayner & Edward J. Mills. (2021) A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Research 5, pages 117.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases

Citations (7)

Articles from other publishers (7)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date